In a Reversal, Sarepta Says It Will Pause Shipments of Gene Therapy Linked to Deaths

Sarepta had initially declined the FDA’s request to pause all shipments of Elevidys.

The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

In a reversal, the drugmaker Sarepta Therapeutics said July 21 it is stopping all shipments of a gene therapy that has been linked to multiple deaths.

Sarepta said in a statement it will voluntarily, and temporarily, halt all shipments of Elevidys at the close of business on July 22.